CRVS Pump?
Float and volume are looking good along with the percentage gain so far. Read the news and watch this into earnings! Just taking a little note here to check back later in my new scanner parameters!
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.93 USD
−27.03 M USD
0.00 USD
49.95 M
About Corvus Pharmaceuticals, Inc.
Sector
CEO
Richard A. Miller
Headquarters
Burlingame
Website
Founded
2014
FIGI
BBG009F0TGH8
Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in Burlingame, CA.
CRVS Short Entry and CoverI put an order our premarket to go short CRVS at the 3.50 level at 3.45. With a target half way back to the 3.00 level at 3.21. The reason I made my target half way to the 3.00 support is not entirely clear to me. Something about how the stock is not very extended, and how volume has been low. it fe
CRVS Covered at lossI covered some CRVS today at a loss. I am currently too lazy to look and get all of the details.
KalaGhazi | Corvus Pharmaceuticals Corvus Pharmaceuticals Extends Gains in Premarket Thursday After Reporting 'Strong Progress' in Immune Diseases Treatment
On Wednesday, the company said it will present new data for CPI-818 at the International Conference on Malignant Lymphoma meeting in Lugano, Switzerland from June 13 to 17.
$CRVSCorvus Pharmaceuticals, Inc. (NASDAQ: CRVS) shares jumped 135.4% to settle at $5.32 on Friday. The stock possibly traded higher following favorable data results by AstraZeneca for patients with unresectable, stage 3 non-small cell lung cancer.
Corvus Pharmaceuticals, Inc., a clinical stage biopharm
$CRVS Corvus Pharmaceuticals Potential Friday Pump Pt's
Hopefully you find the chart helpful in terms of Supports & Resistance etc.
we refrain from adding commentary on the chart as that is reserved for our members and we are very conscious of not giving financial or trading advice.
Thank you for taking time to consult our chart and we would really a
$CRVS Bullish Bat CRVS has a Bullish Bat
HOP Levels: .24 cents
.382 fib $3.75
.618 fib $4.93
on the weekly chart it is a strong green candle, but as for the Daily candle we do have a major gap, meaning we could refill that GAP between $2.53 - $3.57
CRVS - Long Setup Downward channel breakout insider a larger downward channel. Break 2.86 Target 3.43 and Target 2 5.43. Would consider stop of 2.37. Larger risk as stock as already just broken out. January $5.00 calls had 262 contracts traded on Friday. Price is 0.19 cents. $2.50 calls are 0.70.
My CRVS Price TargetsHello all,
As you all may have noticed from doing your research that there has been a quantifiable spike in insider buying by the President and Director of Orbimed Advisors.
On February 17th, 2021 there was an Initial Public Offering at $3.50/share.
I have not made any extensive due diligence on
CRVS Long IdeaMultiple insider buying, huge institutional purchase at $3.50, and clear stop-loss below it. Low risk high reward play. First target is $5.
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of CRVS is 8.24 USD — it has decreased by −1.90% in the past 24 hours. Watch Corvus Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Corvus Pharmaceuticals, Inc. stocks are traded under the ticker CRVS.
CRVS stock has fallen by −17.27% compared to the previous week, the month change is a 15.24% rise, over the last year Corvus Pharmaceuticals, Inc. has showed a 456.76% increase.
We've gathered analysts' opinions on Corvus Pharmaceuticals, Inc. future price: according to them, CRVS price has a max estimate of 24.00 USD and a min estimate of 12.00 USD. Watch CRVS chart and read a more detailed Corvus Pharmaceuticals, Inc. stock forecast: see what analysts think of Corvus Pharmaceuticals, Inc. and suggest that you do with its stocks.
CRVS reached its all-time high on Mar 28, 2017 with the price of 22.14 USD, and its all-time low was 0.61 USD and was reached on Mar 28, 2023. View more price dynamics on CRVS chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
CRVS stock is 4.74% volatile and has beta coefficient of 0.76. Track Corvus Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is Corvus Pharmaceuticals, Inc. there?
Today Corvus Pharmaceuticals, Inc. has the market capitalization of 529.48 M, it has decreased by −5.30% over the last week.
Yes, you can track Corvus Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
Corvus Pharmaceuticals, Inc. is going to release the next earnings report on Mar 6, 2025. Keep track of upcoming events with our Earnings Calendar.
CRVS earnings for the last quarter are −0.60 USD per share, whereas the estimation was −0.11 USD resulting in a −445.45% surprise. The estimated earnings for the next quarter are −0.12 USD per share. See more details about Corvus Pharmaceuticals, Inc. earnings.
Corvus Pharmaceuticals, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
CRVS net income for the last quarter is −40.22 M USD, while the quarter before that showed −4.26 M USD of net income which accounts for −843.62% change. Track more Corvus Pharmaceuticals, Inc. financial stats to get the full picture.
No, CRVS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 21, 2024, the company has 28.00 employees. See our rating of the largest employees — is Corvus Pharmaceuticals, Inc. on this list?
Like other stocks, CRVS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Corvus Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Corvus Pharmaceuticals, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Corvus Pharmaceuticals, Inc. stock shows the buy signal. See more of Corvus Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.